Nucleoside News and Research

RSS

Study: Pathogenetic downregulation of adenosine linked to restless leg syndrome

Researchers have identified a common mechanism implicating adenosine in the cause of restless leg syndrome symptoms — the periodic limb movements characteristic of RLS and the state of enhanced arousal that both disrupt sleep.

4 Apr 2019

Johns Hopkins scientists find new compound that may prevent reperfusion injury

In a strategic search, Johns Hopkins scientists created and screened a library of 45,000 new compounds containing chemical elements of widely used immune system suppressants, and say they found one that may prevent reperfusion injury, a tissue-damaging and common complication of surgery, heart attack and stroke.

21 Feb 2019

MTN launches new study to empower teen girls with choices in HIV prevention

AIDS is already the leading cause of death among girls and young women in much of Africa, and matters could only get worse, given that for every day that passes, 1,000 more girls ages 15 to 24 are likely to become infected with HIV.

8 Feb 2019

Researchers describe first case of patient affected by dysfunctions in SLC28 gene family

A research team has described the first case of a patient affected by dysfunctions in a nucleoside transporter of the SLC28 gene family, which brings a set of genes which were not related to human pathologies in the scientific bibliography so far.

5 Feb 2019

New research may help treat HIV patients without elevating risk for liver disease

As a raft of new treatments for HIV infection have come on the market in the past 20 years, AIDS patients got access to drugs that allowed them to live longer.

1 Feb 2019

FDA approves new treatment for people with hairy cell leukemia

AstraZeneca and MedImmune, its global biologics research and development arm, announced today that the US Food and Drug Administration has approved LUMOXITI (moxetumomab pasudotox-tdfk) for the treatment of adult patients with relapsed or refractory hairy cell leukemia who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog.

14 Sep 2018

Novel treatment for hairy cell leukemia approved by FDA

The U.S. Food and Drug Administration today approved Lumoxiti (moxetumomab pasudotox-tdfk) injection for intravenous use for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog.

14 Sep 2018

New study aims to develop nucleoside therapy as treatment for mitochondrial depletion syndromes

Hundreds of types of mitochondrial disease affect up to 38 million people worldwide, yet there are very few effective treatments, forcing patients and doctors to rely on symptom management to battle the serious and potentially fatal genetic disorder that starves the body’s cells of energy.

27 Jul 2018

HIV patients on single-tablet regimen show better outcomes than those taking multiple pills

HIV patients on a single-tablet daily regimen had better treatment retention and viral suppression than patients taking multiple pills, in a study by a Michael E. DeBakey Veterans Affairs Medical Center researcher and his colleagues.

18 May 2018

Scientists find how immune system helps to clear HBV infection after treatment interruption

Scientists from Karolinska Institutet and Hannover Medical School have published two studies that provide insights into how the immune system responds and helps to clear a hepatitis B infection after treatment interruption.

17 May 2018

New long-acting delivery system has potential to lessen side effects from NRTIs

An HIV diagnosis, while no longer constituting a death sentence, brings with it a lifetime, daily regimen of medication to help continually combat the virus.

27 Mar 2018

IPM begins first clinical trial of vaginal rings to prevent HIV in women

The nonprofit International Partnership for Microbicides announced today the start of the first clinical trial of vaginal rings designed to slowly release the antiretroviral drug dapivirine over three months to prevent HIV in women.

13 Dec 2017

Study finds potential chemical compound that initiated life on Earth

A new study conducted at The Scripps Research Institute (TSRI) has found a compound called diamidophosphate (DAP), which is expected to have played a vital role in the origins of life on Earth.

8 Nov 2017

BioAscent to manage Medivir’s expanding compound library

BioAscent Discovery Limited has taken delivery of Medivir AB’s compound collection of around 56,000 samples, to manage on an outsourced basis.

24 Aug 2017

Injectable ART may have same effectiveness as standard oral treatments

Antiretroviral therapy (ART) intramuscularly administered may have the same effectiveness as current oral treatments.

3 Aug 2017

New antiviral drug candidate effective against broad range of coronaviruses

A new antiviral drug candidate inhibits a broad range of coronaviruses, including the SARS and MERS coronaviruses, a multi-institutional team of investigators reports this week in Science Translational Medicine.

29 Jun 2017

CCNY scientists develop rapid method for preparing molecules with potential against HIV

As the HIV/AIDS epidemic approaches its fourth decade, each year brings promising news of pioneering research to alleviate the scourge.

20 Jun 2017

Scientists reveal new mRNA method to deliver safe, cost-effective therapeutic antibodies

Using antibodies to treat disease has been one of the great success stories of early 21st-century medicine. Already five of the ten top-selling pharmaceuticals in the United States are antibody products. But antibodies are large, complex proteins that can be expensive to manufacture.

2 Mar 2017

New Zika vaccine candidate shows potential to protect against virus with single dose

A new Zika vaccine candidate has the potential to protect against the virus with a single dose, according to a research team led by scientists from the Perelman School of Medicine at the University of Pennsylvania.

2 Feb 2017

Study compares medications for treatment of persons with recurrent genital herpes

In a study appearing in the December 20 issue of JAMA, Anna Wald, M.D., M.P.H., of the University of Washington & Fred Hutchinson Cancer Research Center, Seattle, and colleagues compared the medications pritelivir and valacyclovir for reducing genital herpes simplex virus shedding and lesions in persons with recurrent genital herpes.

20 Dec 2016